.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA03_Obinutuzumab.Obinutuzumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA03_Obinutuzumab.Obinutuzumab| name: | Obinutuzumab |
| ATC code: | L01FA03 | route: | intravenous |
| n-compartments | 2 |
Obinutuzumab is a glycoengineered humanized type II anti-CD20 monoclonal antibody used primarily in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. It acts by targeting the CD20 antigen on B lymphocytes, resulting in cell lysis. Obinutuzumab is approved for clinical use in various countries.
Pharmacokinetic parameters reported for adult patients with relapsed or refractory CD20-positive B-cell malignancies following intravenous administration.
Zhai, J, et al., & Shi, J (2017). Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. British journal of clinical pharmacology 83(7) 1446–1456. DOI:10.1111/bcp.13232 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28072473
Hoy, SM (2015). Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. Drugs 75(3) 285–296. DOI:10.1007/s40265-014-0340-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25586272
Qin, Y, et al., & Shi, Y (2018). Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. Cancer communications (London, England) 38(1) 31–None. DOI:10.1186/s40880-018-0300-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29843792